Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Net Cash Flow came in at -$406.1 million in Q4 2025, down 1488.37% YoY from $29.2 million in Q4 2024, and down 12567.21% on a QoQ basis from $3.3 million in Q3 2025.
Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Net Cash Flow data on file, last reported at -$406.1 million in Q4 2025.
- Quarterly Net Cash Flow fell 1488.37% year-over-year to -$406.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$272.5 million (down 218.99% YoY) and the FY2025 annual result came in at -$272.5 million, down 218.99% from the prior year.
- Net Cash Flow eased to -$406.1 million in Q4 2025, from $3.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $160.6 million in Q1 2025 to a low of -$406.1 million in Q4 2025.
- A 5-year average of $1.1 million and a median of $900500.0 in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 5071.22% — and 2025, when it slumped 1488.37%.
- Tracing KROS's Net Cash Flow over 5 years: stood at $8.7 million in 2021, then surged by 355.84% to $39.6 million in 2022, then grew by 9.17% to $43.3 million in 2023, then plunged by 32.38% to $29.2 million in 2024, then tumbled by 1488.37% to -$406.1 million in 2025.
- The last three Net Cash Flow figures came in at -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -406.06 Mn |
| Dec 31, 2025 | -406.06 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | -30.33 Mn |
| Jun 30, 2025 | -30.33 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | 125.06 Mn |
| Sep 30, 2024 | 125.06 Mn |
| Jun 30, 2024 | -36.58 Mn |
| Jun 30, 2024 | -36.58 Mn |
| Mar 31, 2024 | 111.30 Mn |
| Mar 31, 2024 | 111.30 Mn |
| Dec 31, 2023 | 43.25 Mn |
| Dec 31, 2023 | 43.25 Mn |
| Sep 30, 2023 | -34.25 Mn |
| Sep 30, 2023 | -34.25 Mn |